Ionis Announces Submission of Marketing Authorization Application for Inotersen to the EMA Post author:Sam Post published:November 2, 2017 Post category:BioPharma The MAA will be reviewed under the EMA’s Accelerated Assessment program. Source: BioSpace You Might Also Like SEC Filings Reveal GlaxoSmithKline's 13% Stake in This Massachusetts Biotech November 16, 2017 NantHealth's Expands His Empire With Plans to Open a World-Class Cancer Center This Summer June 8, 2017 Sangamo Receives Fast Track Designation From The FDA For SB-318 And SB-913 In Vivo Genome Editing Product Candidates For The Treatment Of MPS I And MPS II July 13, 2017
NantHealth's Expands His Empire With Plans to Open a World-Class Cancer Center This Summer June 8, 2017
Sangamo Receives Fast Track Designation From The FDA For SB-318 And SB-913 In Vivo Genome Editing Product Candidates For The Treatment Of MPS I And MPS II July 13, 2017
